The Effects of Indobufen on Micro-inflammation and Peritoneal Transport Function in Patients Undergoing Continuous Ambulate Peritoneal Dialysis: A Prospective Randomized Controlled Study .

Introduction: Indobufen possesses anti-coagulant and anti-thrombotic effects,which can improves micro-inflammatory and improves renal function.To indicate whether indobufen could improve micro-inflammatory state in patients undergoing continuous ambulate peritoneal dialysis (CAPD) and to explore its therapeutic effects on peritoneal transport function. Methods: A total of 60 patients who underwent CAPD in our hospital from October 2019 to October 2020 were selected and randomly assigned into control group or indobufen group. Patients in both groups received conventional treatments. Besides, blood routine, and the levels of tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), cellular fibronectin (cFN), and vascular endothelial growth factor (VEGF) in serum and peritoneal effusion were determined before treatment and at 6 months after treatment. Peritoneal equilibrium test (PET) was used to evaluate peritoneal transport function. Results: There were no significant differences in PET result, micro-inflammatory state, and biochemical indices between the two groups before treatment(P>0.05).After 6 months of treatment, PLR and TNF-α level in serum and peritoneal effusion in indobufen group significantly decreased compared with those in the control group(P>0.05); TGF-β1 and cFN levels in serum and peritoneal effusion in indobufen group were markedly reduced compared with those in the control group(P>0.05); PET result in the indobufen group notably decreased compared with that before self-treatment (P>0.05);the difference in PET result between the two groups before and after treatment was statistically significant(P>0.05). Conclusion: Indobufen could improve the peritoneal transport function in patients undergoing CAPD, and the underlying mechanism may be related to the improvement of micro-inflammatory state and peritoneal fibrosis. Significance Statement Micro-inflammation and peritoneal fibrosis can lead to Peritoneal failure in CAPD. Indobufen is a novel antiplatelet drugs that can alleviate renal fibrosis and improve renal function in patients with diabetic nephropathy. Indobufen can improve the peritoneal transport function in patients undergoing CAPD. The mechanism of indobufen improving the peritoneal function may be related to the improvement of micro-inflammatory state and peritoneal fibrosis. Indobufen may have a certain degree of preventive effect on cardiovascular events on patients undergoing CAPD.